Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5139620 | 0.84 | GABRA1 (0.48) | GABRA1GABRB2MEN1KMT2AALDH1A1 | |
| SCHEMBL2362269 | 0.83 | GABRA1 (0.61) | GABRA1GABRB2MEN1KMT2AALDH1A1 | |
| SCHEMBL5403129 | 0.78 | GABRA1 (0.55) | GABRA1GABRB2MEN1KMT2AALDH1A1 | |
| SCHEMBL18136 | 0.77 | GABRA1 (0.56) | GABRA1GABRB2MEN1KMT2AALDH1A1 | |
| SCHEMBL860550 | 0.76 | GABRA1 (0.47) | GABRA1GABRB2MEN1KMT2AALDH1A1 | |
| SCHEMBL2362467 | 0.75 | GABRA1 (0.52) | GABRA1GABRB2MEN1KMT2AALDH1A1 | |
| SCHEMBL9777394 | 0.74 | GABRA1 (0.50) | GABRA1GABRB2MEN1KMT2AALDH1A1 | |
| SCHEMBL1646866 | 0.72 | GABRA1 (0.49) | GABRA1GABRB2MEN1KMT2AALDH1A1 | |
| Bromide SCHEMBL27823869 | 0.72 | GABRA1 (0.49) | GABRA1GABRB2MEN1KMT2AKDM4E | |
| SCHEMBL9003490 | 0.72 | GABRA1 (0.47) | GABRA1GABRB2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224183-B1 | HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050137216-A1 | Heterocyclic sodium/proton exchange inhibitors and method | AHMAD SALEEM (US) | 2005-06-23 | — | — | US | claimed |
| US-6887870-B1 | Heterocyclic sodium/proton exchange inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-03 | — | — | US | claimed |
| EP-1224183-A2 | HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-24 | — | — | EP | claimed |
| WO-2001027107-A2 | HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-19 | — | — | WO | claimed |
| US-7326705-B2 | Heterocyclic sodium/proton exchange inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1224183-B1 | HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050137216-A1 | Heterocyclic sodium/proton exchange inhibitors and method | AHMAD SALEEM (US) | 2005-06-23 | — | — | US | disclosed |
| US-6887870-B1 | Heterocyclic sodium/proton exchange inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1224183-A2 | HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001027107-A2 | HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
| EP-0158137-B1 | PYRIMIDINES | MERCK PATENT GmbH (DE) | 1990-01-10 | — | — | EP | disclosed |
| EP-0158137-A2 | Pyrimidines | MERCK PATENT GmbH (DE) | 1985-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137216-A1 | Heterocyclic sodium/proton exchange inhibitors and method | NHERF1, SLC9A3, SLC9A1 | GABRA1 2714/4885GABRB2 3579/4885MEN1 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.